Inna Zhuranskaya (CFO/COO) and Judy Kingswolf-Yamakawa (Commercial Development Executive) recently attended BioTrinity, where they engaged with a broad spectrum of leaders across the life sciences ecosystem. During the event, they met with major pharmaceutical companies including Ipsen, Eli Lilly, GSK, and Genentech, as well as a range of investors and emerging startups focused on neurodegenerative diseases.
These discussions provided valuable insights into current industry priorities, partnership opportunities, and evolving investment trends. Their participation reinforced the importance of cross-sector collaboration in advancing innovative therapies, particularly in the challenging and rapidly growing field of neurodegeneration.